Poxviridae Infections Drug Market Report

Global and Region Poxviridae Infections Drug Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：234
  • REPORT CODE：GMM924003
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Poxviridae Infections Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Poxviridae Infections Drugmarket, defines the market attractiveness level of Poxviridae Infections Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Poxviridae Infections Drug industry, describes the types of Poxviridae Infections Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Poxviridae Infections Drug market and the development prospects and opportunities of Poxviridae Infections Drug industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Poxviridae Infections Drug market in Chapter 13.

    By Player:

    • Verrica Pharmaceuticals Inc

    • Tonix Pharmaceuticals Holding Corp

    • Bavarian Nordic A/S

    • EpiVax, Inc

    • BioFactura, Inc

    • SIGA Technologies, Inc

    • Takeda Pharmaceutical Company Limited

    • Chimerix, Inc

    • China Biologic Products, Inc

    • CEL-SCI Corporation

    • CJ HealthCare Corp

    • N & N Pharmaceuticals Inc

    By Type:

    • CJ-40011

    • 24a

    • BA-368

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Poxviridae Infections Drug Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Poxviridae Infections Drug Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Poxviridae Infections Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Poxviridae Infections Drug Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Poxviridae Infections Drug Market Analysis and Outlook to 2022

    • 7.1 Global Poxviridae Infections Drug Consumption (2017-2022)

    • 7.2 United States Poxviridae Infections Drug Consumption (2017-2022)

    • 7.3 Europe Poxviridae Infections Drug Consumption (2017-2022)

    • 7.4 China Poxviridae Infections Drug Consumption (2017-2022)

    • 7.5 Japan Poxviridae Infections Drug Consumption (2017-2022)

    • 7.6 India Poxviridae Infections Drug Consumption (2017-2022)

    • 7.7 South Korea Poxviridae Infections Drug Consumption (2017-2022)

    8 Region and Country-wise Poxviridae Infections Drug Market Analysis and Outlook to 2028

    • 8.1 Global Poxviridae Infections Drug Consumption Forecast (2022-2028)

    • 8.2 United States Poxviridae Infections Drug Consumption Forecast (2022-2028)

    • 8.3 Europe Poxviridae Infections Drug Consumption Forecast (2022-2028)

    • 8.4 China Poxviridae Infections Drug Consumption Forecast (2022-2028)

    • 8.5 Japan Poxviridae Infections Drug Consumption Forecast (2022-2028)

    • 8.6 India Poxviridae Infections Drug Consumption Forecast (2022-2028)

    • 8.7 South Korea Poxviridae Infections Drug Consumption Forecast (2022-2028)

    9 Global Poxviridae Infections Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Poxviridae Infections Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global CJ-40011 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global 24a Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global BA-368 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Poxviridae Infections Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Poxviridae Infections Drug Market Outlook by Types and Applications to 2028

    • 10.1 Global Poxviridae Infections Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global CJ-40011 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global 24a Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global BA-368 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Poxviridae Infections Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Poxviridae Infections Drug Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Poxviridae Infections Drug Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Poxviridae Infections Drug Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Poxviridae Infections Drug Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Poxviridae Infections Drug Market Competitive Analysis

    • 14.1 Verrica Pharmaceuticals Inc

      • 14.1.1 Verrica Pharmaceuticals Inc Company Details

      • 14.1.2 Verrica Pharmaceuticals Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Verrica Pharmaceuticals Inc Poxviridae Infections Drug Product and Service

    • 14.2 Tonix Pharmaceuticals Holding Corp

      • 14.2.1 Tonix Pharmaceuticals Holding Corp Company Details

      • 14.2.2 Tonix Pharmaceuticals Holding Corp Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Tonix Pharmaceuticals Holding Corp Poxviridae Infections Drug Product and Service

    • 14.3 Bavarian Nordic A/S

      • 14.3.1 Bavarian Nordic A/S Company Details

      • 14.3.2 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Bavarian Nordic A/S Poxviridae Infections Drug Product and Service

    • 14.4 EpiVax, Inc

      • 14.4.1 EpiVax, Inc Company Details

      • 14.4.2 EpiVax, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 EpiVax, Inc Poxviridae Infections Drug Product and Service

    • 14.5 BioFactura, Inc

      • 14.5.1 BioFactura, Inc Company Details

      • 14.5.2 BioFactura, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 BioFactura, Inc Poxviridae Infections Drug Product and Service

    • 14.6 SIGA Technologies, Inc

      • 14.6.1 SIGA Technologies, Inc Company Details

      • 14.6.2 SIGA Technologies, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 SIGA Technologies, Inc Poxviridae Infections Drug Product and Service

    • 14.7 Takeda Pharmaceutical Company Limited

      • 14.7.1 Takeda Pharmaceutical Company Limited Company Details

      • 14.7.2 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product and Service

    • 14.8 Chimerix, Inc

      • 14.8.1 Chimerix, Inc Company Details

      • 14.8.2 Chimerix, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Chimerix, Inc Poxviridae Infections Drug Product and Service

    • 14.9 China Biologic Products, Inc

      • 14.9.1 China Biologic Products, Inc Company Details

      • 14.9.2 China Biologic Products, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 China Biologic Products, Inc Poxviridae Infections Drug Product and Service

    • 14.10 CEL-SCI Corporation

      • 14.10.1 CEL-SCI Corporation Company Details

      • 14.10.2 CEL-SCI Corporation Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 CEL-SCI Corporation Poxviridae Infections Drug Product and Service

    • 14.11 CJ HealthCare Corp

      • 14.11.1 CJ HealthCare Corp Company Details

      • 14.11.2 CJ HealthCare Corp Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 CJ HealthCare Corp Poxviridae Infections Drug Product and Service

    • 14.12 N & N Pharmaceuticals Inc

      • 14.12.1 N & N Pharmaceuticals Inc Company Details

      • 14.12.2 N & N Pharmaceuticals Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 N & N Pharmaceuticals Inc Poxviridae Infections Drug Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Poxviridae Infections Drug

    • Figure Poxviridae Infections Drug Picture

    • Table Global Poxviridae Infections Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Poxviridae Infections Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Poxviridae Infections Drug Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Poxviridae Infections Drug Consumption by Country (2017-2022)

    • Figure United States Poxviridae Infections Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Poxviridae Infections Drug Consumption and Growth Rate (2017-2022)

    • Figure China Poxviridae Infections Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Poxviridae Infections Drug Consumption and Growth Rate (2017-2022)

    • Figure India Poxviridae Infections Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Poxviridae Infections Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Poxviridae Infections Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Poxviridae Infections Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Poxviridae Infections Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Poxviridae Infections Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Poxviridae Infections Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Poxviridae Infections Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Poxviridae Infections Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CJ-40011 Consumption and Growth Rate (2017-2022)

    • Figure Global 24a Consumption and Growth Rate (2017-2022)

    • Figure Global BA-368 Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global CJ-40011 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global 24a Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global BA-368 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Poxviridae Infections Drug Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Poxviridae Infections Drug Export by Region (Top 5 Countries) (2017-2028)

    • Table Verrica Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Verrica Pharmaceuticals Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Verrica Pharmaceuticals Inc Poxviridae Infections Drug Product and Service

    • Table Tonix Pharmaceuticals Holding Corp (Foundation Year, Company Profile and etc.)

    • Table Tonix Pharmaceuticals Holding Corp Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Tonix Pharmaceuticals Holding Corp Poxviridae Infections Drug Product and Service

    • Table Bavarian Nordic A/S (Foundation Year, Company Profile and etc.)

    • Table Bavarian Nordic A/S Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bavarian Nordic A/S Poxviridae Infections Drug Product and Service

    • Table EpiVax, Inc (Foundation Year, Company Profile and etc.)

    • Table EpiVax, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table EpiVax, Inc Poxviridae Infections Drug Product and Service

    • Table BioFactura, Inc (Foundation Year, Company Profile and etc.)

    • Table BioFactura, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioFactura, Inc Poxviridae Infections Drug Product and Service

    • Table SIGA Technologies, Inc (Foundation Year, Company Profile and etc.)

    • Table SIGA Technologies, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table SIGA Technologies, Inc Poxviridae Infections Drug Product and Service

    • Table Takeda Pharmaceutical Company Limited (Foundation Year, Company Profile and etc.)

    • Table Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product and Service

    • Table Chimerix, Inc (Foundation Year, Company Profile and etc.)

    • Table Chimerix, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Chimerix, Inc Poxviridae Infections Drug Product and Service

    • Table China Biologic Products, Inc (Foundation Year, Company Profile and etc.)

    • Table China Biologic Products, Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table China Biologic Products, Inc Poxviridae Infections Drug Product and Service

    • Table CEL-SCI Corporation (Foundation Year, Company Profile and etc.)

    • Table CEL-SCI Corporation Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table CEL-SCI Corporation Poxviridae Infections Drug Product and Service

    • Table CJ HealthCare Corp (Foundation Year, Company Profile and etc.)

    • Table CJ HealthCare Corp Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table CJ HealthCare Corp Poxviridae Infections Drug Product and Service

    • Table N & N Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table N & N Pharmaceuticals Inc Poxviridae Infections Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table N & N Pharmaceuticals Inc Poxviridae Infections Drug Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US